Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran Etexilate Tablet vs Solution
NCT02170922Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1999
- Primary completion
- Aug 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in venous thromboembolism (VTE) and stroke (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the curve of BIBR 953 ZW at 48 hours, Maximum plasma concentration of BIBR 953 ZW at 48 hours and 1 more. Started Jul 1999; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
venous thromboembolism (VTE)stroke
Beyond the preview
Go deeper on NCT02170922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170922.